Successful attempts to correct trafficking defects using molecular chaperones have been reported for CFTR mutants causing cystic fibrosis or lysosomal storage disorders (Zegarra-Moran and Galietta, 2017; Platt, 2018). Here, CFTR is linked to lysosomal storage disease.